| Previous Section | Index | Home Page |
19 Oct 2006 : Column 1437W—continued
Older People (Health Services)
Mr. Drew: To ask the Secretary of State for Health what plans she has to continue to monitor the implementation of (a) the standard six criteria of the national service framework for older people and (b) the National Institute for Health and Clinical Excellence guidance on the secondary prevention of osteoporotic fractures; and if she will make a statement. [93081]
Mr. Ivan Lewis: The Department continues to monitor implementation of standard six of the national service framework for older people through the ongoing Royal College of Physicians' national audit of falls and bone health services.
Implementation of the National Institute for Health and Clinical Excellence guidance, on the secondary prevention of osteoporotic fractures, continues to be managed by strategic health authorities.
Rosiglitazone
Mr. Dunne: To ask the Secretary of State for Health (1) when Rosiglitazone is expected to be made available to patients most at risk of developing diabetes; [93260]
(2) what estimate she has made of the likely annual cost to the NHS of providing Rosiglitazone to those likely to benefit from it; [93261]
(3) what representations she has received about the estimated number of patients who would benefit from Rosiglitazone. [94046]
Ms Rosie Winterton: Rosiglitazone is not licensed for the prevention of type 2 diabetes.
No estimate has been made of the likely annual cost to the national health service of providing Rosiglitazone to those likely to benefit from it. However, the following data show the current costs to the NHS for prescribing Rosiglitazone:
| Net ingredient costs for the dispensing of glitazones | |||
| Dispensing in the community | |||
| £ | |||
| Pioglitazone | Metformin/Rosiglitazone | Rosiglitazone | |
| Dispensing in hospitals | |||
| £ | |||
| Pioglitazone | Metformin/Rosiglitazone | Rosiglitazone | |
The National Institute for Health and Clinical Excellence (NICE) published recommendations in 2003 on the use of glitazones for the treatment of type 2 diabetes. NICE is currently reviewing this guidance as part of a review of all of its type 2 diabetes guidance which is due to be published in February 2008.
I have received no representations about the estimated number of patients who would benefit from Rosiglitazone.
Sexually Transmitted Diseases
Jim Cousins: To ask the Secretary of State for Health how many diagnoses of sexually transmitted infections (a) in total and (b) of (i) HIV, (ii) syphilis, (iii) gonorrhoea, (iv) Chlamydia, (v) herpes, (vi) genital warts and (vii) non specific infections there were in each year since 1995 in (A) the North East and (B) each primary care trust area in the North East. [93945]
Caroline Flint: The information requested at the primary care trust level is not available centrally. Information at strategic health authority (SHA) level is given in the following tables. HIV data is collected through a different process than data on sexually transmitted infections and is therefore shown separately.
Diagnoses of sexually transmitted infections (STIs) in total, North East Region
| Table 1. Total number of new diagnoses at GUM clinics by year for the North East Region | |||||||||||
| 1995 | 1996 | 1997 | 1998 | 1999 | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | |
Diagnoses of STI, North East Region
| Table 2: Number of specific diagnoses of STI at GUM clinics by year for the North East Region | |||||||||||
| Diagnoses | 1995 | 1996 | 1997 | 1998 | 1999 | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 |
Diagnoses of STIs in total, North East Region
| Table 3: Total number of new diagnoses at GUM clinics by year for the North East. | |||||||||||
| SHA | 1995 | 1996 | 1997 | 1998 | 1999 | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 |
Diagnoses of STI, North East Region
| Next Section | Index | Home Page |